Graft failure after allogeneic islet transplantation in a patient with type 1 diabetes and a high anti-glutamic acid decarboxylase antibody titer.
J Diabetes Investig
; 14(5): 725-729, 2023 May.
Article
de En
| MEDLINE
| ID: mdl-36860136
ABSTRACT
Pancreatic islet transplantation is a ß-cell replacement therapy for people with insulin-deficient diabetes who have difficulty in glycemic control and suffer from frequent severe hypoglycemia. However, the number of islet transplantations carried out is still limited in Asia. We report a case of allogeneic islet transplantation in a 45-year-old Japanese man with type 1 diabetes. Although the islet transplantation was successfully carried out, graft loss was observed on the 18th day. Immunosuppressants were used in accordance with the protocol, and donor-specific anti-human leukocyte antigen antibodies were not detected. Autoimmunity relapse was also not observed. However, the patient had a high titer of anti-glutamic acid decarboxylase antibody from before the islet transplantation, and autoimmunity might thus have affected the ß-cells in the transplanted islet. The evidence is still scarce to reach conclusions, and further data accumulation is required to enable proper patient selection before islet transplantation.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Transplantation d'ilots de Langerhans
/
Transplantation de cellules souches hématopoïétiques
/
Diabète de type 1
Type d'étude:
Guideline
Limites:
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
J Diabetes Investig
Année:
2023
Type de document:
Article
Pays d'affiliation:
Japon